Don't want to speak for Dew by my thinking is they are dead because of side-effect or viral load reductions not being up to par with competitors compounds in Phase 1-2.
Is VRTX just naive and thinking that telaprevir can't be improved upon to a much greater degree
I get a kick out of just about every call when they say telaprevir sets a high bar that its hard to improve upon .
It would be huge for ITMN/Roche if BID Telaprevir is a flop and Ritonavir+191 allows for QD dosing (but I'll be happy with lower BID dosing).
AI
. 
